Raffaele Marfella

Active 1993–2025

192
Papers
27,335
Citations
90
h-index
186
i10-index

Citations

Citations per year for Raffaele Marfella1994: 1 citations1995: 2 citations1996: 4 citations1997: 6 citations1998: 13 citations1999: 15 citations2000: 28 citations2001: 27 citations2002: 43 citations2003: 112 citations2004: 254 citations2005: 292 citations2006: 295 citations2007: 268 citations2008: 238 citations2009: 221 citations2010: 204 citations2011: 166 citations2012: 195 citations2013: 173 citations2014: 156 citations2015: 172 citations2016: 130 citations2017: 138 citations2018: 135 citations2019: 443 citations2020: 804 citations2021: 896 citations2022: 767 citations2023: 586 citations2024: 1,300 citations2025: 762 citations2026: 10 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,090 citing papers, 20.6% of this breakdownChina: 1,081 citing papers, 10.7% of this breakdownItaly: 1,035 citing papers, 10.2% of this breakdownUnited Kingdom: 615 citing papers, 6.1% of this breakdownSpain: 346 citing papers, 3.4% of this breakdownGermany: 326 citing papers, 3.2% of this breakdownAustralia: 301 citing papers, 3% of this breakdownCanada: 272 citing papers, 2.7% of this breakdownIndia: 252 citing papers, 2.5% of this breakdownFrance: 223 citing papers, 2.2% of this breakdownJapan: 217 citing papers, 2.1% of this breakdownGreece: 198 citing papers, 2% of this breakdown
0%20.6%Other 31.3%

Fields

  • Medicine76.1%
  • Biochemistry, Genetics and Molecular Biology14.1%
  • Nursing2.1%
  • Neuroscience1.7%
  • Immunology and Microbiology1.7%
  • Environmental Science0.9%
  • Other3.4%

Topics

  • Adipokines, Inflammation, and Metabolic Diseases4.5%
  • Diabetes Treatment and Management4.3%
  • Nutritional Studies and Diet2.8%
  • Diet and metabolism studies2.5%
  • Cardiovascular Function and Risk Factors2.3%
  • COVID-19 Clinical Research Studies2.3%
  • Other81.3%

Coauthors

All papers

Open in search
  1. Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications

    Authors: , , , , , , , , , , , , - Current Issues in Molecular Biology 2023 cited by 506

  2. Microplastics and Nanoplastics in Atheromas and Cardiovascular Events

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Franca Ferraraccio, Iacopo Panarese, Pasquale Paolisso, Emanuele Barbato, Carmine Lubritto, Maria Luisa Balestrieri, Ciro Mauro, A. Enrique Caballero, Sanjay Rajagopalan, Antonio Ceriello, Bruno D’Agostino, Pasquale Iovino, Giuseppe Paolisso - New England Journal of Medicine 2024 cited by 1,002

  3. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives

    Authors: , , , , , , , , - International Journal of Molecular Sciences 2023 cited by 256

  4. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors

    Authors: , , , , , , , , , , , , - International Journal of Molecular Sciences 2022 cited by 240

  5. Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in Humans

    Authors: , , , , , , , , - Circulation 2002 cited by 1,963

  6. Effect of a Mediterranean-Style Diet on Endothelial Dysfunction and Markers of Vascular Inflammation in the Metabolic Syndrome

    Authors: , , , , , , , , - JAMA 2004 cited by 2,118

  7. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry

    Authors: , , , , , , , , , , , , , , , , , , , - Cardiovascular Diabetology 2022 cited by 208

  8. Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials

    Authors: , , , , , , , , , , , - Frontiers in Cardiovascular Medicine 2022 cited by 139

  9. Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes

    Authors: , , , , , , , , , , , , - Pharmacological Research 2022 cited by 137

  10. Peripheral Neuropathy in Diabetes Mellitus: Pathogenetic Mechanisms and Diagnostic Options

    Authors: , , , , , , , , , , , , , , , , , - International Journal of Molecular Sciences 2023 cited by 203

  11. Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Pharmacological Research 2022 cited by 146

  12. SIRT3 mediates the effects of PCSK9 inhibitors on inflammation, autophagy, and oxidative stress in endothelial cells

    Authors: , , , , , , , , , , , - Theranostics 2023 cited by 90

  13. miR-21 in Human Cardiomyopathies

    Authors: , , , , , - Frontiers in Cardiovascular Medicine 2021 cited by 120

  14. SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis

    Authors: , , , , , , , , , , , , , , - Cardiovascular Diabetology 2023 cited by 106

  15. Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies

    Authors: , , , , , , , , - Biomedicines 2023 cited by 81

  16. Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Atherosclerosis 2023 cited by 98

  17. COVID-19 Causes Ferroptosis and Oxidative Stress in Human Endothelial Cells

    Authors: , , , , , , , , , , - Antioxidants 2023 cited by 85

  18. GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes

    Authors: , , , , , , , , , , , , , , , , - Cardiovascular Diabetology 2024 cited by 65

  19. Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , - Biology 2023 cited by 113

  20. Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options

    Authors: , , , , , , , , , , , , , - Biomedicines 2022 cited by 92

  21. Effect of Weight Loss and Lifestyle Changes on Vascular Inflammatory Markers in Obese Women

    Authors: , , , , , , - JAMA 2003 cited by 1,482

  22. SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes

    Authors: , , , , , , , , , , , , , , , , , , , , - BMC Medicine 2023 cited by 104

  23. In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Frontiers in Cardiovascular Medicine 2022 cited by 88

  24. Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Diabetes Research and Clinical Practice 2023 cited by 79